Table 3.

Association of TLR1 rs5743618 with clinical outcome in the TRIBE and FIRE-3 cohorts

PFSOS
RRUnivariateaMultivariateaUnivariateaMultivariatea
Genotypenn (%)PMedian month (95% CI)HR (95% CI)PHR (95% CI)PMedian month (95% CI)HR (95% CI)PHR (95% CI)P
TRIBE
 G/G5029 (60%)10.8 (8.8–12.6)1 (Reference)1 (Reference)23.2 (16.4–37.6)1 (Reference)1 (Reference)
 G/T13281 (63%)0.07710.5 (9.4–11.3)0.92 (0.63–1.34)0.0450.89 (0.60–1.34)0.12028.6 (25.6–33.5)0.95 (0.65–1.39)0.0240.94 (0.63–1.40)0.077
 T/T4418 (43%)8.2 (7.5–9.7)1.48 (0.93–2.35)1.38 (0.85–2.25)19.9 (15.1–24.0)1.57 (0.99–2.49)1.46 (0.91–2.36)
 Any G182110 (62%)0.02510.5 (9.5–11.2)1 (Reference)0.0141 (Reference)0.04627.9 (25.0–33.0)1 (Reference)0.0071 (Reference)0.025
 T/T4418 (43%)8.2 (7.5–9.7)1.57 (1.09–2.28)1.50 (1.01–2.22)19.9 (15.1–24.0)1.63 (1.14–2.35)1.53 (1.06–2.23)
FIRE-3
 G/G14795 (68%)10.7 (9.1–12.3)1 (Reference)1 (Reference)24.2 (19.4–27.4)1 (Reference)1 (Reference)
 G/T8745 (58%)0.02010.1 (9.0–13.2)0.94 (0.70–1.26)0.4660.98 (0.73–1.31)0.55926.9 (21.3–31.0)0.88 (0.63–1.22)0.3350.84 (0.61–1.18)0.332
 T/T5222 (46%)10.1 (8.5–11.3)1.18 (0.84–1.67)1.19 (0.84–1.67)23.1 (15.1–28.0)1.19 (0.83–1.72)1.15 (0.79–1.67)
 Any G234140 (65%)0.02110.4 (9.3–11.9)1 (Reference)0.2441 (Reference)0.28624.8 (21.5–27.6)1 (Reference)0.2051 (Reference)0.265
 T/T5222 (46%)10.1 (8.5–11.3)1.21 (0.87–1.68)1.20 (0.86–1.66)23.1 (15.1–28.0)1.25 (0.88–1.77)1.22 (0.86–1.74)
  • NOTE: Correlations with P < 0.05 are marked with bold text.

  • aP value was based on Fisher exact test for tumor response, log-rank test for PFS and OS in the univariable analysis.

  • bP value was based on Wald test in the multivariable Cox proportional hazards regression model adjusting age, ECOG performance status, primary tumor site, number of metastatic sites, resection of the primary tumors, RAS mutation status, adjuvant chemotherapy in TRIBE cohort; adjusting for sex, ECOG performance status, liver limited metastasis, primary tumor resection, and KRAS mutation status in FIRE3 cohort.